DE60324806D1 - Entzündungshemmende di- und trifluortriazolopyridin-verbindungen - Google Patents

Entzündungshemmende di- und trifluortriazolopyridin-verbindungen

Info

Publication number: DE60324806D1
Authority: DE; Germany
Prior art keywords: trifluoropyridine; inflammatory; compounds; trifluoropyridine compounds
Prior art date: 2002-08-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60324806T

Other languages

English (en)

Inventor

Mark Dombroski

Michael LETAVIC

Kim Francis Mcclure

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pfizer Products Inc

Original Assignee

Pfizer Products Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-30

Filing date

2003-08-19

Publication date

2009-01-02

2003-08-19 Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc

2009-01-02 Application granted granted Critical

2009-01-02 Publication of DE60324806D1 publication Critical patent/DE60324806D1/de

2023-08-20 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Transplantation (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Toxicology (AREA)
Vascular Medicine (AREA)

DE60324806T 2002-08-30 2003-08-19 Entzündungshemmende di- und trifluortriazolopyridin-verbindungen Expired - Lifetime DE60324806D1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US40717702P	2002-08-30	2002-08-30
PCT/IB2003/003847 WO2004020440A1 (en)	2002-08-30	2003-08-19	Di and trifluoro-triazolo-pyridines anti-inflammatory compounds

Publications (1)

Publication Number	Publication Date
DE60324806D1 true DE60324806D1 (de)	2009-01-02

Family

ID=31978432

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60324806T Expired - Lifetime DE60324806D1 (de)	2002-08-30	2003-08-19	Entzündungshemmende di- und trifluortriazolopyridin-verbindungen

Country Status (17)

Country	Link
US (1)	US7259171B2 (de)
EP (1)	EP1537108B1 (de)
JP (1)	JP2006504680A (de)
AR (1)	AR041078A1 (de)
AT (1)	ATE414705T1 (de)
AU (1)	AU2003259438A1 (de)
BR (1)	BR0313965A (de)
CA (1)	CA2494754A1 (de)
DE (1)	DE60324806D1 (de)
ES (1)	ES2315560T3 (de)
GT (1)	GT200300187A (de)
MX (1)	MXPA05002304A (de)
PA (1)	PA8579601A1 (de)
PE (1)	PE20040978A1 (de)
TW (1)	TW200420562A (de)
UY (1)	UY27961A1 (de)
WO (1)	WO2004020440A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2515190A1 (en) *	2003-02-14	2004-08-26	Pfizer Products Inc.	Triazolo-pyridines as anti-inflammatory compounds
BRPI0514391A (pt) *	2004-08-18	2008-06-10	Pharmacia & Upjohn Co Llc	compostos de triazolopiridina para o tratamento de inflamação
ES2301380B1 (es)	2006-08-09	2009-06-08	Laboratorios Almirall S.A.	Nuevos derivados de 1,7-naftiridina.
AU2007307031B2 (en) *	2006-10-11	2011-11-24	Amgen Inc.	Imidazo- and triazolo-pyridine compounds and methods of use therof
ES2320955B1 (es)	2007-03-02	2010-03-16	Laboratorios Almirall S.A.	Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
ES2329639B1 (es)	2007-04-26	2010-09-23	Laboratorios Almirall S.A.	Nuevos derivados de 4,8-difenilpoliazanaftaleno.
EP1992344A1 (de)	2007-05-18	2008-11-19	Institut Curie	P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind
EP2108641A1 (de)	2008-04-11	2009-10-14	Laboratorios Almirall, S.A.	Neue substituierte Spiro[Cycloalkyl-1,3'-indo]-2'(1'H)-on-Derivate und ihre Verwendung als p38 mitogen-activated Kinase Inhibitoren
EP2113503A1 (de)	2008-04-28	2009-11-04	Laboratorios Almirall, S.A.	Neue substituierte Indolin-2-on- Derivate und ihre Verwendung als p39 mitogen-activated Kinase Inhibitoren
RS56410B1 (sr) *	2009-07-27	2018-01-31	Gilead Sciences Inc	Fuzionisana heterociklična jedinjenja kao modulatori jonskih kanala
EP2322176A1 (de)	2009-11-11	2011-05-18	Almirall, S.A.	Neue 7-Phenyl-[1,2,4]triazol[4,3-a]pyridin-3(2H)on-Derivate
WO2012003392A1 (en)	2010-07-02	2012-01-05	Gilead Sciences, Inc.	Fused heterocyclic compounds as ion channel modulators
CN105693645B (zh)	2011-05-10	2018-10-09	吉利德科学公司	作为离子通道调节剂的稠合杂环化合物
TWI478908B (zh)	2011-07-01	2015-04-01	Gilead Sciences Inc	作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (de)	2011-07-01	2018-04-28
EP2875014B1 (de)	2012-07-17	2017-11-29	Washington University	Schleimlösungsarzneien und verwendungen dafür
EP3842424B1 (de)	2013-03-15	2024-12-11	The Trustees of Columbia University in the City of New York	Map-kinasemodulatoren und verwendungen davon zur behandlung von tauopathien
GB201511382D0 (en)	2015-06-29	2015-08-12	Imp Innovations Ltd	Novel compounds and their use in therapy
WO2017151409A1 (en)	2016-02-29	2017-09-08	University Of Florida Research Foundation, Incorporated	Chemotherapeutic methods
MX2020003961A (es)	2017-10-05	2020-09-22	Fulcrum Therapeutics Inc	Uso de inhibidores de p38 para reducir la expresion de dux4.
US10342786B2 (en)	2017-10-05	2019-07-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN109867617A (zh) *	2019-04-03	2019-06-11	南京格亚医药科技有限公司	一种4-甲氧基吡咯中间体的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5716972A (en)	1993-01-13	1998-02-10	Smithkline Beecham Corporation	Pyridyl substituted imidazoles
CN1048731C (zh)	1993-09-17	2000-01-26	史密丝克莱恩比彻姆公司	编码细胞因子抑制性抗炎药物结合蛋白质的多核苷酸
DE69433501T2 (de)	1993-11-08	2004-11-04	Smithkline Beecham Corp.	Oxazole zur behandlung von zytokinvermittelten erkrankungen
US5717100A (en)	1995-10-06	1998-02-10	Merck & Co., Inc.	Substituted imidazoles having anti-cancer and cytokine inhibitory activity
ZA97175B (en)	1996-01-11	1997-11-04	Smithkline Beecham Corp	Novel substituted imidazole compounds.
JP2000503302A (ja)	1996-01-11	2000-03-21	スミスクライン・ビーチャム・コーポレイション	新規置換イミダゾール化合物
GB9713726D0 (en)	1997-06-30	1997-09-03	Ciba Geigy Ag	Organic compounds
CA2333157A1 (en)	1998-05-26	1999-12-02	Smithkline Beecham Corporation	Novel substituted imidazole compounds
US6207687B1 (en)	1998-07-31	2001-03-27	Merck & Co., Inc.	Substituted imidazoles having cytokine inhibitory activity
US6350744B1 (en)	1998-11-20	2002-02-26	Merck & Co., Inc.	Compounds having cytokine inhibitory activity
JP4634613B2 (ja)	1998-12-16	2011-02-16	アベンティス・フアーマ・リミテッド	ヘテロアリール環状アセタール類
WO2000040243A1 (en)	1999-01-08	2000-07-13	Smithkline Beecham Corporation	Novel compounds
IL144144A0 (en)	1999-01-13	2002-05-23	Bayer Ag	Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
CO5170501A1 (es) *	1999-04-14	2002-06-27	Novartis Ag	AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO
EP1370557B1 (de)	2001-03-09	2005-11-16	Pfizer Products Inc.	Entzündungshemmende benzimidazolverbindungen
MXPA03008144A (es) *	2001-03-09	2003-12-12	Pfizer Prod Inc	Nuevos compuestos antiinflamatorios de triazolopiridinas.
ES2247271T3 (es)	2001-04-04	2006-03-01	Pfizer Products Inc.	Nuevos benzotriazoles como compuestos antiinflamatorios.

2003
- 2003-08-05 PA PA20038579601A patent/PA8579601A1/es unknown
- 2003-08-19 AT AT03791145T patent/ATE414705T1/de not_active IP Right Cessation
- 2003-08-19 BR BR0313965-4A patent/BR0313965A/pt not_active IP Right Cessation
- 2003-08-19 ES ES03791145T patent/ES2315560T3/es not_active Expired - Lifetime
- 2003-08-19 JP JP2004532622A patent/JP2006504680A/ja not_active Withdrawn
- 2003-08-19 DE DE60324806T patent/DE60324806D1/de not_active Expired - Lifetime
- 2003-08-19 MX MXPA05002304A patent/MXPA05002304A/es active IP Right Grant
- 2003-08-19 AU AU2003259438A patent/AU2003259438A1/en not_active Abandoned
- 2003-08-19 CA CA002494754A patent/CA2494754A1/en not_active Abandoned
- 2003-08-19 EP EP03791145A patent/EP1537108B1/de not_active Expired - Lifetime
- 2003-08-19 WO PCT/IB2003/003847 patent/WO2004020440A1/en active Application Filing
- 2003-08-25 PE PE2003000863A patent/PE20040978A1/es not_active Application Discontinuation
- 2003-08-27 US US10/649,236 patent/US7259171B2/en not_active Expired - Fee Related
- 2003-08-28 AR ARP030103118A patent/AR041078A1/es unknown
- 2003-08-29 TW TW092123952A patent/TW200420562A/zh unknown
- 2003-08-29 GT GT200300187A patent/GT200300187A/es unknown
- 2003-08-29 UY UY27961A patent/UY27961A1/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
UY27961A1 (es)	2004-03-31
US20040053958A1 (en)	2004-03-18
PA8579601A1 (es)	2004-05-07
US7259171B2 (en)	2007-08-21
EP1537108A1 (de)	2005-06-08
EP1537108B1 (de)	2008-11-19
ATE414705T1 (de)	2008-12-15
WO2004020440A1 (en)	2004-03-11
JP2006504680A (ja)	2006-02-09
ES2315560T3 (es)	2009-04-01
CA2494754A1 (en)	2004-03-11
AR041078A1 (es)	2005-04-27
GT200300187A (es)	2004-06-23
AU2003259438A1 (en)	2004-03-19
MXPA05002304A (es)	2005-06-08
TW200420562A (en)	2004-10-16
BR0313965A (pt)	2005-07-19
PE20040978A1 (es)	2004-12-28

Publication	Publication Date	Title
ATE368042T1 (de)	2007-08-15	Cephemverbindungen
IS7471A (is)	2004-10-15	Ný efnasambönd
NO20052914D0 (no)	2005-06-15	Terapeutiske forbindelser
IS7362A (is)	2004-07-22	Kínasólín efnasambönd
DE60324806D1 (de)	2009-01-02	Entzündungshemmende di- und trifluortriazolopyridin-verbindungen
IS7879A (is)	2005-06-02	Ný efnasambönd
ATE411996T1 (de)	2008-11-15	Kondensierte azolpyrimidinderivate
ATE309997T1 (de)	2005-12-15	Entzündungshemmende benzimidazolverbindungen
IS7381A (is)	2004-08-03	Efnasambönd
DE10393374D2 (de)	2005-09-01	Zusammensetzung
IS7414A (is)	2004-08-19	Oxó-azabísýklísk efnasambönd
DK3006462T3 (da)	2019-06-17	Alfa-1-antitrypsin-sammensætning
NO20045659L (no)	2004-12-27	Forbindelser
DE60327447D1 (de)	2009-06-10	Pflaster
IS7793A (is)	2005-04-11	Nýtt efnasamband
IS7827A (is)	2005-04-27	Ný efnasambönd
IS7794A (is)	2005-04-11	Nýtt efnasamband
NO20055612D0 (no)	2005-11-25	Anti-inflammatoriske fosfonatforbindelser
SE0500163L (sv)	2005-01-24	Sammansättning
AU2003282510A8 (en)	2004-05-04	Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents
DK1691814T3 (da)	2012-10-29	Antiinflammatoriske midler
EP1561467A4 (de)	2008-06-25	Zusammensetzung zur wiederherstellung geschädigter haut
DE10390373D2 (de)	2004-12-09	Phosphorchelatverbindungen
DE60328488D1 (de)	2009-09-03	Ng
DE60307471D1 (de)	2006-09-21	Hemmung

Legal Events

Date	Code	Title	Description
2009-12-10	8364	No opposition during term of opposition